May 20, 2024 by admin aurigene Targeting CBM, A Tri Protein Signalling Hub, By Inhibition Of MALT1 For The Treatment Of B- Cell Lymphomas
May 20, 2024 by admin aurigene A Highly Differentiated Small Molecule Immune Checkpoint Inhibitor Dually Targeting PD-L1 And A2AR For Cancer Therapy
April 3, 2024 by admin aurigene SMARCA2/4 degraders relieve the differentiation block in AML via changes in chromatin looping and accessibility
April 3, 2024 by admin aurigene Targeting the SWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies
April 3, 2024 by admin aurigene Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer
April 3, 2024 by admin aurigene Discovery of potent and paralog selective PROTAC degraders of CBP or p300 proteins for the treatment of various cancers
April 3, 2024 by admin aurigene Identification of paralog selective degraders of SMARCA2 and SMARCA4 for treatment of various cancers
April 3, 2024 by admin aurigene Targeting CBP/p300 – Inhibition vs. Degradation for Potent Anti-Tumor Efficacy
April 3, 2024 by admin aurigene Targeting CBP/p300 – Inhibition vs Degradation for Potent Anti-tumor Efficacy, Drug Discovery Chemistry
April 3, 2024 by admin aurigene Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer
